Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil
MetadataShow full item record
AbstractOne strategy to address hyperprolactinemia and associated sexual side effects in patients receiving antipsychotics is switching to an antipsychotic not associated with prolactin elevation (eg, aripiprazole). This post hoc analysis assessed prolactin concentrations and sexual side effects in an open-label prospective study of switching long-acting injectable antipsychotics from paliperidone palmitate (PP) to aripiprazole lauroxil (AL). Serum prolactin was measured throughout the study. Patient-reported sexual and endocrine side effects were assessed on the UKU Side Effect Rating Scale sexual function subscale and analyzed in study completers. Prior to starting AL treatment (screening), 49/50 (98%) patients had prolactin concentrations above the upper limit of normal (ULN; >13.13 ng/mL [males]; >26.72 ng/mL [females]). Six months after beginning AL treatment, prolactin levels were above ULN in 2/32 (6.3%) patients. Among 32 study completers, 81.3% reported sexual dysfunction in ≥1 domain at screening versus 56.3% at 6 months after starting AL treatment. Diminished sexual desire was the most common patient-reported sexual complaint at screening (46.9%); at 6 months, it was reported by 18.8%. In this post hoc analysis, the high levels of prolactin observed at screening decreased during AL treatment, and modest improvements in sexual side effects were evident in patients with schizophrenia.
Rights/TermsCopyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.
Dopamine D2 receptor antagonists
Drug side effects
Sexual dysfunction, physiological
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/16058
- Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY.
- Authors: Potkin SG, Loze JY, Forray C, Baker RA, Sapin C, Peters-Strickland T, Beillat M, Nylander AG, Hertel P, Steen Andersen H, Eramo A, Hansen K, Naber D
- Issue date: 2017 May
- Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D<sub>2/3</sub> receptor blockade - An exploratory study.
- Authors: Düring SW, Nielsen MØ, Bak N, Glenthøj BY, Ebdrup BH
- Issue date: 2019 Apr
- Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate.
- Authors: Montalvo I, Ortega L, López X, Solé M, Monseny R, Franch J, Vilella E, Labad J
- Issue date: 2013 Jan
- Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil.
- Authors: Nasrallah HA, Aquila R, Stanford AD, Jamal HH, Weiden PJ, Risinger R
- Issue date: 2017 Aug 1
- Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period.
- Authors: Weiden PJ, Du Y, Liu CC, Stanford AD
- Issue date: 2019 Aug